Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash from Investing Activities (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Cash from Investing Activities readings, the most recent being -$350.0 million for Q4 2025.

  • Quarterly Cash from Investing Activities fell 270.97% to -$350.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$298.0 million through Dec 2025, down 2301.64% year-over-year, with the annual reading at -$298.0 million for FY2025, 2301.64% down from the prior year.
  • Cash from Investing Activities hit -$350.0 million in Q4 2025 for Terns Pharmaceuticals, down from $24.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $47.2 million in Q4 2023 and bottomed at -$350.0 million in Q4 2025.
  • Average Cash from Investing Activities over 5 years is -$24.5 million, with a median of $359500.0 recorded in 2022.
  • Peak annual rise in Cash from Investing Activities hit 88960.0% in 2021, while the deepest fall reached 20392.16% in 2021.
  • Terns Pharmaceuticals' Cash from Investing Activities stood at -$6.4 million in 2021, then tumbled by 126.54% to -$14.5 million in 2022, then skyrocketed by 424.71% to $47.2 million in 2023, then crashed by 299.75% to -$94.3 million in 2024, then crashed by 270.97% to -$350.0 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Cash from Investing Activities are -$350.0 million (Q4 2025), $24.5 million (Q3 2025), and $25.5 million (Q2 2025).